

エバリュエート 日本の医薬品市場予測

日本市場動向


日本の医薬品市場は、2017年から2022年まで年平均3.3% (CAGR) で成長と予測。
全世界の医薬品の年平均成長6.5%に対し、かなり低いと予測。

The enforcement of a much more stringent pricing revision policy, both for new products as well as off-patent brands, is behind the decline of the products currently in the market which are forecast to drop by around 2% annually.

Japan Total Market Sales (\$bn)

Marketed and R&D

Source: Evaluate Japan Drug Forecasts*, June 2017




The prices of Gilead's HCV blockbuster Sovaldi and Harvoni have been subject to significant price scrutiny and most recently the Japanese government has forced a price reduction of 50% on Opdivo, BMS' novel PD-1/PD-L1 agent.

However, the sales decline of marketed products is counterbalanced by the optimism surrounding the new therapies - expected to account for 34% of the Japanese market in 2022.

Japan Total Market Sales (¥bn)

Marketed and R&D

Source: Evaluate Japan Drug Forecasts, June 2017



Note: *In 2012 there was a decline in the value of the yen leading to a decline in dollar value of the Japanese Pharmaceutical market.